期刊文献+

大鼠肠黏膜靶向磁共振对比剂Gd-DTPA-CPs成像 被引量:2

Gd-DTPA-chitosan particles as a magnetic resonance contrast agent for rat's intestinal mucosa targeted imaging
下载PDF
导出
摘要 目的制备肠黏膜靶向磁共振对比剂Gd-DTPA-CPs,探讨其用于大鼠活体肠黏膜MR成像的可行性。方法采用改良的乳化微滴融合法制备Gd-DTPA-CPs,经过结构表征和细胞毒性试验后对正常大鼠进行MRI。对大鼠行灌肠前MR扫描,之后将其分为两组,分别经直肠灌注Gd-DTPA-CPs溶液(实验组)和Gd-DTPA溶液(对照组)后于不同时间点行MR扫描,测量各时间点肠壁和盆壁肌肉信号强度,计算肠壁的相对信号值和强化率。扫描完成后取相应肠段行病理学检查。结果 Gd-DTPA-CPs直径约420 nm,药物包封率为74.41%,分散度较好,体外细胞毒性小。实验组灌肠前、后各时间点肠壁相对信号值差异有统计学意义(F=23.77,P<0.05),保留灌肠20 min时出现最大差异,最大强化率达35%。经电镜证实实验组大鼠Gd-DTPA-CPs聚集于结肠黏膜上皮细胞内;对照组灌肠前后各扫描时间点相对信号值差异无统计学意义(F=0.15,P>0.05),结肠上皮细胞内无Gd-DTPA聚集。结论本实验制备的Gd-DTPA-CPs能与正常肠黏膜结合,提示可通过直肠给药途径进行活体大鼠肠黏膜MRI。 Objective To synthesize Gd-DTPA-chitosan particles,and to explore its feasibility and potential application as an intestinal mucosa targeted MR contrast agent by enteroclysis.Methods Gd-DTPA-CPs was synthesized by modified emulsion coalescence method,then the physical and chemical properties were identified.Gd-DTPA-CPs(Gd-DTPA-CPs group) and Gd-DTPA(Gd-DTPA group) was administrated to healthy rats with enteroclysis.MR scans were performed before enteroclysis and after clysis reservation at different time point.The signal intensity of intestinal wall and muscles of the pelvis were measured and the relative signal intensity values were calculated.Immediately after MR scanning,the rats were killed and intestinal segments were separated for pathological study.Results The prepared Gd-DTPA-CPs was 420 nm in diameter with a 74.41% Gd-DTPA content.The degree of dispersion was good and the cytotoxicity in vitro was low.The relative signal intensity value of intestinal wall at any time point after infusion in Gd-DTPA-CPs group was statistically higher than that observed before enteroclysis(F=23.77,P0.05).The signal intensity of the colon mucosa was highest at 20 min.No significantly difference was found before and after infusion in Gd-DTPA group(F=0.15,P0.05).Transmission electron microscopy images showed that Gd-DTPA-CPs localized inside the mucosal cells or intercellular space,while positive particles were not observed in intestinal mucosa of Gd-DTPA group.Conclusion Gd-DTPA-CPs were successfully prepared,which could be adhered and absorbed by intestinal mucosa,suggesting that it can be used as a potential intestinal mucosa targeted MR contrast agent by enteroclysis.
出处 《中国医学影像技术》 CSCD 北大核心 2012年第1期40-43,共4页 Chinese Journal of Medical Imaging Technology
基金 上海市科委基础重点项目(08JC1415100) 上海市重点学科(S30203)
关键词 磁共振成像 壳聚糖 钆DTPA 肠黏膜 Magnetic resonance imaging Chitosan Gadolinium DTPA Intestinal mucosa
  • 相关文献

参考文献10

  • 1Aime S, Cabella C, Colombatto S, et al. Insights into the use of paramagnetic Gd ( III ) complexes in MR-molecular imaging inves tigations. J MagnReson Imaging, 2002, 16(4):394-406.
  • 2Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med, 1999,5(4):387-391.
  • 3Chandy T, Das GS, Rao GH. 5 Fluorouracil loaded chitosan coa ted polylactic acid microspheres as biodegradable drug carriers for cerebraltumours. J Microencapsul, 2000,17(5):625 -638.
  • 4Gupta KC, Jabrail FH. Glutaraldehyde and glyoxal cross linked chitosan microspheres for controlled delivery of centchroman. Carbohydr Res, 2006,341(6) :744- 756.
  • 5Kato Y, Onishi H, Machida Y. Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotechnol, 2003,4(5) :303- 309.
  • 6Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan gadopentetic acid complex nanoparticles for gadolinium neutron capture therapy of cancer: Preparation by novel emulsion droplet coalescence technique and characterization. Pharm Res, 1999,16(12):1830 1835.
  • 7郑伟良,章士正,孙继红,吴涛,纪建松,郑豪,郑树.钆喷替酸葡甲胺-壳聚糖颗粒载体在小鼠肠壁吸附的MRI研究[J].中华放射学杂志,2008,42(1):24-28. 被引量:2
  • 8Brasch RC. Rationale and applications for macromolecular Gd based contrast agents. MagnReson Med, 1991,22(2):282 -287.
  • 9Kun PH, Kanal E, Abu Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology, 2007,242(3) :647- 649.
  • 10Behrens I, Pena AI, Alonso MJ, et al. Comparative uptake studies of bioadhesive and non bioadhesivenanoparticles in hu- man intestinal cell lines and rats : The effect of mucus on particle adsorption and transport. Pharm Res, 2002, 19(8) :1185- 1193.

二级参考文献14

  • 1刘朝阳,傅军,田海梅,邵长君,刘义,李茉,曲平,张伟.氟尿嘧啶壳聚糖缓释剂瘤内注射治疗小鼠肝癌的实验研究[J].癌症进展,2005,3(2):173-178. 被引量:6
  • 2Muzzarelli C, Muzzarelli RA. Natural and artificial chitosaninorganic composites. J Inorg Biochem, 2002,92:89-94.
  • 3Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery property of chitosan nanoparticles. Int J Pharm, 2003, 250 : 215-226.
  • 4Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 2004, 56: 1649-1659.
  • 5Kim TH, Park IK, Nah JW, et aL Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier. Biomaterials,2004,25:3783-3792.
  • 6Kim TH, Jin H, Kim HW, et al. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells . Mol Cancer Ther,2006,5 : 1723-1732.
  • 7Tokumitsu H, Ichikawa H, Saha TK, et al. Design and preparation of gadolinium-loaded chitosan particles for cancer neutron capture therapy. Stp Pharma Sciences, 2000,10: 39-49.
  • 8Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release, 2001,75:409-419.
  • 9Janes KA, Fresenean MR, Marazuela A, et al. Chitosan nanoparticles as deliver system for doxorubicin. J Control Release, 2001,73:255-267.
  • 10Luessen HL, Lehr CM, Rentel CO, et al. Bioadhesive polymers for the poroal delivery of peptide drugs. J Control Release, 1994, 29:329-338.

共引文献1

同被引文献19

  • 1周丽华,黄光文.激光扫描共聚焦显微镜在植物学中的应用[J].激光生物学报,2005,14(1):76-79. 被引量:20
  • 2朱炯,许建荣,周滟,李磊,朱震亚.小肠克罗恩病的MRI诊断与小肠钡灌肠的比较分析[J].医学影像学杂志,2006,16(5):489-491. 被引量:6
  • 3王维英,邓钢.移植细胞的影像学示踪[J].中国医学影像技术,2006,22(5):782-784. 被引量:3
  • 4武乐斌,李春卫.小肠影像学检查与诊断的发展现状[J].医学影像学杂志,2008,18(1):1-3. 被引量:7
  • 5Foxman B. The epidemiology of urinary tract infection[J]. Nat Rev Urol,2010,7(12) :653-660.
  • 6Hirji I, Guo Z, Andersson S W, et al. Incidence of urinary Iract infection among patients witb type 2 diabetes in the UK General Practice Research Database (GPRI)) [ J ]. J Diabetes Complications, 2012,26(6):513- 516.
  • 7Pieri L, Sassoli C, Romagnoli P, et al. Use of periodate-lysine- paraformaldehyde for the fixation of multiple antigens in human skin hiopsies[J]. Eur J Histoehem,2002,46(4) :365-375.
  • 8Welch R A, Burland V, Plunkett G 3rd, et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Eseherichia coli[J]. Proc Nat Acad Sci U S A, 2002, 99 (26): 17020-17024.
  • 9Melican K, Richter-Dahlfors A. Real-time live imaging to study bacterial infections in vivo[J]. Curr Opin Microbiol, 2009,12 (1) : 31-36.
  • 10Steed E, Balda M S, Matter K. Dynamics and functions of tight junctions[J]. Trends Cell Biol, 2010,20 (3) : 142- 149.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部